Fobi Corporate Update Includes Completion Of Several Pilot Tests Now In Advanced Terms Negotiations, $10.42M in Funding And Uplist To Major Exchange
VANCOUVER, British Columbia, July 16, 2021 (GLOBE NEWSWIRE) -- FOBI AI Inc. (TSXV: FOBI) (OTCQB: FOBIF:) (the "Company" or "FOBI"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement is pleased to provide shareholders with the following corporate update regarding the following significant company initiatives.
Fobi CEO Rob Anson states, “Despite the challenges presented by the pandemic in getting our pilot tests adequately evaluated by our major international retailers, I am happy to report that multiple pilots have successfully made it over the finish line and that 2021 is on track to be the year Fobi becomes a major global player in the world of real-time data analytics. Add to this our most powerful balance sheet ever, Tier-1 global partnerships, a rapidly expanding executive team of industry stalwarts and the acquisition of Passcreator, I can unequivocally report that Fobi is in the strongest position it has ever been and that shareholders will realize its benefits far beyond 2021.”
MULTIPLE PILOT PROJECTS INCLUDING SOBEYS, CERTAS, PHARMASSIST AND OTHERS NOW COMPLETED. ADVANCING TOWARDS NEGOTIATED COMMERCIAL TERMS AND ROLL OUTS.
Fobi announced several large-scale pilot projects early in 2021 that ended up taking longer than expected to complete due to COVID-19 restrictions in the workplaces of our pilot partners. Nonetheless, with restrictions around the world easing over the past several weeks and pilot partners able to scale pilot transactions with the resulting capacity increases, many of our pilot projects have now successfully ended and advanced to corporate and legal review of proposed commercial terms and roll out.
Moreover, a couple of our pilot projects have demonstrated such success that pilot partners are expanding the scope of their pilots with the addition of digital receipting, wallet pass loyalty applications, digital activations, and promotions.
The currently disclosed list of pilot projects includes Sobeys, TELUS, Certas, Pharmassist, Maplin and Senor Frogs, with several discussions in advanced stages with world renowned hospitality, sports and entertainment venues.
FOBI ON TRACK WITH PLAN TO UPLIST TO MAJOR EXCHANGES IN FOURTH QUARTER
On December 7, 2020, Fobi announced its intentions to uplist to the Toronto Stock Exchange and, if successful, its intentions to apply for listing on the NASDAQ. Given the Company’s continued success with world-renowned technology pilots and partners, our anticipated significant growth in 2021 and the inevitable need for significantly greater capital markets visibility, Fobi is pleased to advise shareholders that we continue to work through the checklist of requirements and processes to achieve our uplisting goals by the end of the year.
PRIVATE PLACEMENT AND WARRANT EXERCISES TOTALLING OVER $10.42 MILLION IN WORKING CAPITAL TO FUND OPERATIONS AND FURTHER STRATEGIC ACQUISITIONS
In anticipation of our corporate and capital markets growth requirements in 2021, Fobi received strong shareholder support as demonstrated by the most recent $7.42 Million private placement in which Fobi CEO, Rob Anson, personally invested $350,000, raising his year to date investments to over $750,000.
SENIOR MANAGEMENT TEAM NOW IN PLACE AND READY TO EXECUTE
With the recent additions of Former NielsenIQ Richard Lee as SVP of Corporate Strategy, as well as former NTT Data executive Jolie Summers as VP of Product, Fobi’s Senior Management Team is complete and well positioned to execute on the incredible opportunities in our pipeline. Richard Lee brings 10 years of experience with Nielsen to Fobi and he has already played a big part in negotiating current strategic acquisition opportunities. Jolie Summers brings extensive product experience to Fobi and has already begun the process of productizing existing core product functionalities, as well as defining exciting new commercial product offerings set to launch in the near future.
PASSCREATOR GENERATES OVER $160,000 CDN REVENUE IN Q1
Passcreator had one of the best quarters in its history, realizing $161,630 CDN of revenue in the first quarter. Significant new deals with several of its existing customers such as Mercedes and BMW and a new deal with a global company operating in 29 countries around the world, led to a 188% increase in revenue YOY. There are additional large deals with these customers, as well as with 3 of the largest insurance companies in the world that are being negotiated right now for Q3 & Q4.
The acquisition of Passcreator is already paying off with significant recurring revenue, as well as commencement of negotiations with several of its largest Wallet pass customers and prospects to implement Fobi devices.
FOBI is a cutting-edge data intelligence company that helps our clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits. FOBI's unique IoT device has the ability to integrate seamlessly into existing infrastructure to enable data connectivity across online and on-premise platforms creating highly scalable solutions for our global clients. FOBI partners with some of the largest companies in the world to deliver best-in-class solutions and operates globally in the retail, telecom, sports & entertainment, casino gaming, and hospitality & tourism industries.
For more information, please contact:
|FOBI AI Inc.||FOBI Website: www.fobi.ai|
|Rob Anson, CEO||Facebook: @ FOBIinc|
|T: +1 877-754-5336 Ext. 4||Twitter: @ FOBI_inc|
|E: firstname.lastname@example.org||LinkedIn: @ FOBIinc|
This news release contains certain statements which constitute forward-looking statements or information, including statements relating to the use of proceeds from the Offering. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company's control, including the impact of general economic and capital markets conditions, stock market volatility and the ability to access sufficient capital from internal and external sources. Although the Company believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future plans, operations, results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the included forward looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of the Company should be considered highly speculative. There can be no assurance that the Company will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Leading Edge Materials Announces Filing of Preliminary Economic Assessment Report for Woxna Graphite Anode Project26.7.2021 14:30:00 CEST | Press release
Vancouver, July 26, 2021 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) is pleased to announce that the technical report for its Woxna Graphite project (the “Project”) titled “NI 43-101 Technical Report – Woxna Graphite” with effective date June 9, 2021, has been filed under the Company’s profile on SEDAR today (the “Report” or “PEA”). The Report supports the disclosure in the Company’s news release dated June 9, 2021. All figures in the Report are US dollars unless otherwise specified. The news release on June 9, 2021, presented these highlights of the Report: Main PEA Highlights The PEA indicates the potential viability of a Swedish operation producing battery grade graphite anode material utilizing an existing graphite mine and concentrator with the addition of a value-add processing facility offsite;The proposed process route in the PEA uses a thermal purification process which, combined with access
Cavotec wins key motorised cable reel order for advanced container cranes in Japan26.7.2021 09:00:00 CEST | Press release
Cavotec has won a key order for its innovative motorised cable reel systems for integration onto advanced rail-mounted gantry cranes at the Port of Tokyo – a project that highlights Cavotec’s position as a trusted supplier of mission-critical systems at ports and terminals. “Given the complexity of these high-end cranes and their demanding operational environment, this is an excellent reference for us as we continue to grow in Japan and the wider region,” says Robin Shang, Cavotec Regional Sales Director Ports & Maritime. Cavotec will supply motorised cable reel systems for eight automated rail-mounted gantry (ARMG) cranes at the Wan Hai Tokyo Oi5 terminal, a major global container handling hub. The cable reels will ensure the cranes meet demanding performance requirements due to surging container volumes. Working closely with Chin Pan engineering group, Cavotec is scheduled to complete the delivery of the systems in early 2023. Previously, Chin Pan has fitted two ARMGs cranes successf
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.7.2021 08:44:35 CEST | Press release
Company Announcement No. 38/2021 Copenhagen, 26 July 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 19 July to 23 July 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,781,412222,947,59319 July 202120,000125.242,504,78020 July 202115,510125.551,947,26
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity26.7.2021 08:00:00 CEST | Press release
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studiesof Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status. “There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO. Saniona is proud to be pioneering a regulatory path forward for people li
SERSTECH AB: Half-year report 1 January – 30 June 202126.7.2021 08:00:00 CEST | Press release
Serstech Group Second quarter 2021 Net sales: KSEK 2 765 (308)Profit for the period: KSEK -5 299 (-6 820)Earnings per share: SEK -0.06 (-0.10)Earnings per average number of shares: SEK -0.07 (-0.10) Serstech Group Period 1 January - 30 June 2021 Net sales: KSEK 14 224 (6 321)Profit for the period: KSEK -2 270 (-10 025)Earnings per share: SEK -0.03 (-0.14)Earnings per average number of shares: SEK-0.03 (-0.14) The second quarter brought a slight increase in orders received compared to the previous quarter, but we clearly see remaining effects of the pandemic in most parts of the world. We have not lost any tenders during the quarter, which is encouraging and again suggests that there is an unmet demand in the market. We do expect an increase in sales over the next six months, as the buyers become more active and the important demo sessions can be arranged safely again. Buyers in our industry will not buy an instrument they have not tested themselves and therefore they postpone procureme
Reminder of an Investor Conference Webinar26.7.2021 08:00:00 CEST | Press release
We would like to remind that KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the July 29th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who will introduce the performance and unaudited financial results of KN for the six months of 2021. How to join the webinar? To join the webinar, please register via following link: https://register.gotowebinar.com/register/6420133473151346701You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the webinar, opens automatically. The webinar will be recorded and available online for everyone at the company’s we
Van Lanschot Kempen’s partnership with Mercier Vanderlinden finalised26.7.2021 08:00:00 CEST | Press release
’s-Hertogenbosch/Amsterdam, the Netherlands, 26July2021 Van Lanschot Kempen and Mercier Vanderlinden today announced that they have completed the transaction that sees Van Lanschot Kempen acquire a 70% stake in Mercier Vanderlinden. The regulators have issued declarations of no objection, and Van Lanschot Kempen and Mercier Vanderlinden have thus joined forces in the Belgian wealth management market. Van Lanschot Kempen will increase step-by-step its 70% stake in Mercier Vanderlinden to 100%. Mercier Vanderlinden and Van Lanschot Kempen in Belgium will continue to operate independently and collaborate in a number of areas. The partners are a good fit in terms of client portfolios and networks, product offering and geographical coverage. Between them, they had €9.3 billion in client assets at 30 June 2021. In the past few years, both Van Lanschot Kempen in Belgium and Mercier Vanderlinden have achieved robust client asset growth, and they will continue their role as market challengers o